Asset
Zeripatamig
TG Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04806035 | phase1 | terminated | 2021-04-28 | 2024-06-12 | TG Therapeutics, Inc. | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia |
| NCT03804996 | phase1 | completed | 2019-03-05 | 2024-02-21 | TG Therapeutics, Inc. | Study of TG-1801 in Subjects With B-Cell Lymphoma |
FDA applications (0)
This company has no applications containing this asset.